AMPK Pathway Activation Markers in GBM: Expression Patterns and Clinical Associations in a Real-World Study
Fabrizio Ferrarini, Paola Del Bianco, Martina Corrà, Tiziana Talienti et autres
0 citationsInternational Journal of Molecular Sciences
Enrico Franceschi
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
318Publications signalées
10493Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Glioma Diagnosis and TreatmentBrain Metastases and TreatmentRadiomics and Machine Learning in Medical ImagingMeningioma and schwannoma managementNeuroblastoma Research and Treatments
Publications récentes
ID #397 Diagnostic and predictive molecular biomarkers in brain tumors across the lifespan: an age-stratified consensus statement
Federica D’Antonio, Angela Mastronuzzi, Enrico Franceschi, E Benicelli et autres
0 citationsNeuro-Oncology Pediatrics
Caregiver professional employment and its impact on glioblastoma patient survival: Results from two prospective studies.
Vincenzo Di Nunno, Alicia Tosoni, Isacco Desideri, Maria Michiara et autres
0 citationsJournal of Clinical Oncology
Ultrasound-Based Therapies in Primary Central Nervous System Tumors
Giovanni Dima, Alessandro Olivari, V. Di Nunno, Marta Aprile et autres
0 citationsCancers
Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey
Oriol Mirallas, Giulia Cerretti, Anna S. Berghoff, Dieta Brandsma et autres
0 citationsJuSER Publikationsportal
Financial toxicity, Socioeconomic Status, and clinical outcome in Glioblastoma: the ISES-2 Prospective Multicenter Italian Study
Alicia Tosoni, Laura Arenare, Isacco Desideri, Maria Michiara et autres
0 citationsSSRN Electronic Journal
How to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis
Marta Aprile, Vincenzo Di Nunno, Lidia Gatto, Alicia Tosoni et autres
0 citationsFrontiers in Oncology
CTNI-09. VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
Marjolein Geurts, Emilie LeRhun, Giuseppe Minniti, Marta Padovan et autres
0 citationsNeuro-Oncology
OS04.5.A A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209
Enrico Franceschi, Martin J. van den Bent, Marc Sanson, Andrew B. Lassman et autres
0 citationsNeuro-Oncology
P17.40.B EFFECTIVENESS OF TARGET THERAPY IN ADULT AND PEDIATRIC RECURRENT HIGH GRADE GLIOMA PATIENTS WITH BRAFV600E MUTATION OR NTRK FUSION: A REAL-LIFE MULTICENTRIC ITALIAN ANALYSIS.
Eugenia Cella, Matteo Padovan, Albino Claudio Bosio, M Maccari et autres
0 citationsNeuro-Oncology
P17.06.A VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
Marjolein Geurts, Émilie Le Rhun, Giuseppe Minniti, Matteo Padovan et autres
1 citationNeuro-Oncology
Gender- and Grade-Dependent Activation of Androgen Receptor Signaling in Adult-Type Diffuse Gliomas: Epigenetic Insights from a Retrospective Cohort Study
Lidia Gatto, Sofia Asioli, Luca Morandi, Enrico Di Oto et autres
2 citationsBiomedicines
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.